Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Andrew H. Huber
Rbhs Robert Wood Johnson Medical School, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
FFA Sciences
Other : Profit sharing
Dr. Andrew H. Huber is employed by FFA Sciences and will be compensated (b)(4) for his work on this study. FFA Sciences produces the tests that will be used in this study to measure unbound Bilirubin (Bf) and unbound free fatty acid (FFAu). In the event the company profits, Dr. Huber will also be compensated via profit sharing. Hence it is reasonable to conclude that success with the experiments outlined in the grant application may benefit Dr. Huber. The ICOIC concluded that a conflict of interest exists.
Unbound fatty acids, Intralipid and Unbound Bilirubin in Preterm Infants
Unbound Fatty Acids and Unbound Bilirubin in Preterm Infants: The Role of Intralipid Neonatal jaundice occurs in 60-70% of newborns and severe hyperbilirubinemia can lead to neurological dysfunction and possibly death. Current diagnostic techniques measure total serum levels of bilirubin (TSB), which are used as indicators for treatment, however, it is the level of free, unbound bilirubin (Bf) that determines risk of bilirubn neurotoxicity more accurately than TSB. The Bf levels are elevated due to competition for binding sites by compounds including free fatty acids (FFA) which are increased in premature infants treated with Intralipid, an intravenous fatty acid emulsion used to provide calories. The goal of this project is to utilize a new, innovative technology to measure Bf and unbound FFA (FFAu) levels and demonstrate significant elevations of Bf in this population. In addition, another goal is to show that the use of TSB for intervention indications occurs at very high Bf levels. The public health relevance of this project is to establish a new, method for the diagnosis of neonatal jaundice resulting in better protection against bilirubin related neurological injury and more accurate therapeutic interventions.
Filed on September 23, 2014.
Tell us what you know about Andrew H. Huber's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Andrew H. Huber”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Andrew H. Huber | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | FFA Sciences | $80,000 - $99,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.